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Ure2p is the protein determinant of the Saccharomyces cerevisiae prion state
[URE3]. Constitutive overexpression of the HSP70 family member SSA1
cures cells of [URE3]. Here, we show that Ssa1p increases the lag time of
Ure2p fibril formation in vitro in the presence or absence of nucleotide.
The presence of the HSP40 co-chaperone Ydj1p has an additive effect on
the inhibition of Ure2p fibril formation, whereas the Ydj1p H34Q mutant
shows reduced inhibition alone and in combination with Ssa1p. In order
to investigate the structural basis of these effects, we constructed and
tested an Ssa1p mutant lacking the ATPase domain, as well as a series of
C-terminal truncation mutants. The results indicate that Ssa1p can bind to
Ure2p and delay fibril formation even in the absence of the ATPase
domain, but interaction of Ure2p with the substrate-binding domain is
strongly influenced by the C-terminal lid region. Dynamic light scattering,
quartz crystal microbalance assays, pull-down assays and kinetic analysis
indicate that Ssa1p interacts with both native Ure2p and fibril seeds, and
reduces the rate of Ure2p fibril elongation in a concentration-dependent
manner. These results provide new insights into the structural and mechan-
istic basis for inhibition of Ure2p fibril formation by Ssa1p and Ydj1p.1. Introduction
Prions are infectious proteins, accounting for a group of invariably fatal neuro-
degenerative diseases in mammals, including Creutzfeldt–Jakob disease in
humans, and bovine spongiform encephalopathy and scrapie in animals [1].
These prion diseases are closely associated with a host-derived protein called
PrP, whose modified isoform is generally thought to be the principal constitu-
ent of the prion particle [1,2]. Normal PrP converts to infectious pathogenic
PrPSc through a refolding process in which the a-helix and random coils
rearrange into a b-sheet structure [3,4]. The discovery that the Saccharomyces
cerevisiae genetic element [URE3] consists of an altered form of the protein
that has the ability to convert normal Ure2p into the altered form [5], broadened
the concept of prions to include transmission of non-fatal or even favourable
traits. The expansion of the prion concept to fungal proteins has allowed signifi-
cant progress in mechanistic understanding of the prion phenomenon, with
yeast genetics providing a powerful complement to biophysical approaches [6].
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Figure 1. Schematic of Ssa1p domain structure and deletion mutants used in
this study. The three-dimensional predicted full-length Ssa1p structure was mod-
elled using ROSSETTADOCK protein–protein docking software (www.rosettacommons.
org) based on the structures of bovine Hsc70 (1yuw) and DnaK (1dkx).
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2Ure2p is a 354-residue protein, composed of two structural
domains with distinct functions [7]. The N-terminal domain is
relatively flexible and protease-sensitive [8,9], and conveys the
ability to switch to a prion state in vivo and to form amyloid-
like fibrils in vitro [10–13]. Recent results have defined a short
fibril-forming peptide region within the N-terminal domain as
a potential initiation point for amyloid formation [14]. The
crystal structure of the C-terminal domain shows similarity
to glutathione S-transferases (GSTs) [15,16], although the
protein lacks typical GST activity [17,18]. However, Ure2p
shows both glutathione-dependent peroxidase activity [19]
and thiol-disulfide oxidoreductase activity [20]. Further, typi-
cal GST activity can be restored by single-site mutation at
the enzyme active site [21]. The ability of Ure2p to bind to
Gln3p, and hence exert its nitrogen catabolite repression
activity, is lost when soluble Ure2p converts into the aggre-
gated [URE3] prion form [10], but the anti-oxidant activity of
Ure2p is maintained in prion strains in vivo [18] and in
amyloid-like fibrils in vitro [19–21].
Heat-shock proteins play an important role in preventing
protein misfolding and aggregation, and the cytosolic HSP70
family is one of the major classes of chaperones involved in reg-
ulating prion propagation [22]. The Ssa subfamily of HSP70
chaperones comprises four members (Ssa1–4) and is essential
for cell viability [23]. Ssa proteins are involved in avariety of cel-
lular processes, such as translation, translocation and general
protein folding [24–26]. SSA1 and SSA2 are constitutively
expressed and their gene products are 96 per cent identical,
whereas SSA3 and SSA4 are heat-shock-inducible and their
gene products are both 80 per cent identical to Ssa1p and Ssa2p.
The only Ssa protein structures published to date are that
of a short C-terminal peptide of Ssa1p in complex with
Sis1p, a co-chaperone of HSP70; or with Tom71, a component
of the mitochondrial translocon [27–29]. However, the HSP70
family shares a highly conserved architecture, consisting of an
N-terminal nucleotide-binding domain (NBD), a substrate-
binding domain (SBD) and a C-terminal lid domain
(CTD) [30–34]. Owing to its ability to hydrolyse adeno-
sine triphosphate (ATP) into adenosine diphosphate (ADP),
the NBD is also termed the ATPase domain. The SBD is a
b-sandwich structure containing a long peptide binding
groove, whereas the a-helical bundle C-terminal domain acts
as a lid, stabilizing the complex of HSP70 and substrate [35].
A model of the Ssa1p structure and the sequence positions
of its domain boundaries are illustrated in figure 1.
The role of the ATPase activity of HSP70 is to modulate its
substrate binding affinity and to facilitate substrate release. In
the ATP binding state, HSP70 tends to release the substrate,
whereas in the ADP binding state, its affinity for the substrate
is relatively high [36–38]. The intrinsic ATPase activity of Ssa1p
is stimulated by co-chaperones, including Ydj1p [39–42]. ATP
binding induces conformational changes in the adjacent
domains, including movement of the lid so that the substrate
binding groove becomes uncovered. By contrast, substrate
binding causes ATP hydrolysis and closure of the lid over
the substrate binding groove [43,44]. Thus, the ATPase cycle
contributes to the efficiency of the essential cellular functions
of HSP70 by promoting substrate binding and release. How-
ever, current understanding of the ATPase cycle of HSP70
has primarily been derived from studies using small peptide
substrates, whereas recent results suggest that the structural
changes associated with substrate binding may be different
for larger substrates [45]. Interestingly, HSP70 is able to bindand prevent aggregation of substrates such as alpha-synuclein
even in the absence of any nucleotide [46–48], suggesting that
the intrinsic chaperone activity of HSP70 may still be main-
tained even without energy generated from ATP hydrolysis.
Recent mutagenesis studies on DnaK show that the ability to
refold luciferase correlates poorly with the rate of ATP turnover
[49]. Further, certain mutants of DnaK can refold luciferase
normally in the absence of any significant ATP turnover, and
also complement a DdnaK strain of Escherichia coli. This indi-
cates that removal of the ATPase function of HSP70 does not
necessarily ablate its ability to protect proteins frommisfolding
and aggregation in vitro and in vivo [49].
Ssa1p shows differing effects on the yeast prions [PSIþ]
and [URE3] in vivo. Constitutive overexpression of Ssa1p
but not the nearly identical Ssa2p cures cells of [URE3] [50].
Additionally, several mutants of Ssa1p and Ssa2p have
been identified that are capable of impairing [URE3] propa-
gation [51]. With regard to [PSIþ], excess Ssa1p protects
[PSIþ] from curing induced by overexpression of HSP104
[52]. [PSIþ] stability is normal in strains that lack SSA1 or
SSA2 [53] and overexpression of Ssa1p increases de novo
[PSIþ] formation [54]. However, recent evidence suggests
that overexpression of either Ssa1p or Ssa2p can cure some
variants of [PSIþ] by increasing the size of prion aggregates
and hence hindering prion transmission to daughter cells
[55]. In vitro studies show that Ssa1p alone does not affect
Sup35p fibril assembly, but can block fibril formation in the
presence of either of its HSP40 co-chaperones, Ydj1p or Sis1p
[56]. The action of HSP104p in promoting fibril formation of
Sup35p is reversed in the presence of complexes of Ssa1p
with its co-chaperones [56]. It has recently been reported that
Ssa1p inhibits Ure2p amyloid fibril formation in the presence
of ATP [57,58]. The co-chaperone Ydj1p can also inhibit
Ure2p fibril formation itself [57,59]. The previous studies indi-
cate that inhibitory effects of both Ssa1p and Ydj1p on Ure2p
fibril formation in vitro depend on the interaction of the
chaperone with the C-terminal region of Ure2p [57,59,60].
The mechanism of how Ssa1p inhibits Ure2p fibril for-
mation is complex and is not yet fully understood. It
remains unclear how specific domains of Ssa1p function
independently or in cohort to produce the observed inhi-
bition of fibril formation of Ure2p. To address these
rstb.royalsociet
3questions, we used the power of in vitro methods to dissect
out the relative contribution of the different Ssa1p structural
domains, by investigating the effect of a series of deletion
mutants of Ssa1p on Ure2p fibril formation. We also investi-
gated in further detail the mode and mechanism of
interaction between Ssa1p and Ure2p. ypublishing.org
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(a) Materials
1,4-Dithiothreitol (DTT), b-mercaptoethanol, Tris, thioflavin T
(ThT), ATP, ADP, creatine kinase (CK) and creatine phosphate
(CP) were purchased from Sigma. TEV (tobacco etch virus) pro-
tease was from Invitrogen. Recombinant firefly luciferase and
luciferase assay kit were from Promega. All other reagents
were local products of analytical grade. Deionized distilled
water was used throughout.
(b) Protein expression and purification
Ure2p was expressed and purified under native conditions as
described previously [8], except that a French press was used to
disrupt the cells. Ydj1p was purified as previously described
and the His-tag was left intact [59]. The Ssa1p expression plasmid
(pPROEX-HTb-Ssa1) was provided by Prof. Susan Lindquist
(available from Adgene as plasmid 1231). The Ssa1p domain-del-
etion mutants were derived from the Ssa1p gene. The boundaries
were determined based on tertiary structure predictions, using the
partial structures of bovine Hsc70 [30] and DnaK [35] (figure 1).
The Ssa1p protein and its truncation mutants were produced
and purified as described [61,62], with some modifications [63].
In brief, the harvested cells were lysed using a JNBIO JN-3000
PLUS high-pressure cell press in buffer A (40 mM Hepes–KOH
buffer, pH 7.4, containing 300 mM KCl, 5% glycerol and 2 mM
b-mercaptoethanol) containing 20 mM imidazole, and the debris
was removed by centrifugation (35 000g, 30 min). The supernatant
was then loaded onto a Ni affinity column (chelating sepharose
fast-flow resin; Pharmacia/GE) and washed with buffer A con-
taining 100 mM imidazole. Protein was eluted using buffer A
containing 350 mM imidazole and dialysed into 50 mM Tris–
HCl buffer pH 8.4 containing 150 mM KCl, 5 mM MgCl2
and 1 mM DTT with or without 5 per cent glycerol (henceforth
abbreviated to ‘Tris buffer pH 8.4’). Treatment with TEV protease
to remove theHis-tagwas followedbya further roundof purification
by Ni affinity chromatography. It was found that the presence or
absence of the His-tag had no effect on the ability of Ssa1p to inhibit
Ure2p fibril formation. Therefore, the His-tagged protein was used
in subsequent experiments. In vivo, when it is the sole HSP70-Ssap
in the cell, His-tagged Ssa1p is well expressed and is able to pro-
vide essential cellular functions [64]. In order to confirm that our
purified Ssa1p had normal ATPase and chaperone functions, we
measured its intrinsic ATPase activity in the presence and absence
of co-chaperone Ydj1 [65,66] (see the electronic supplementary
material, figure S1a) and its ability to refold luciferase [67,68] (see
the electronic supplementary material, figure S1b).
All protein concentrations are given in terms of monomer and
were determined by the absorbance at 280 nm using calculated
extinction coefficients of 48 220 M21 cm21 for Ure2p [8], 19
770 M21 cm21 for Ydj1p [59], 23 970 M21 cm21 for Ssa1p and 14
650 M21 cm21 for DA Ssa1p. The concentration of Ssa1p and its
mutants was also confirmed by bicinchoninic acid assay kit (Pierce).
(c) In vitro amyloid fibril formation
The formation of Ure2p fibrils was monitored by ThT binding
fluorescence as previously described [13,69] on a Hitachi
FL-4500 fluorimeter. Ure2p amyloid fibrils were prepared byincubation of Ure2p at 308C in either a Sim International SI-300
incubator shaking at 220 rpm or in an Innova 4230 incubator
shaking at 300 rpm, and ThT fluorescence was monitored
discontinuously as described [13,69]. Alternatively, samples
were incubated in 96-well plates in a Perkin-Elmer EnSpire multi-
mode plate reader shaking at 900 rpm and 1 mm amplitude at
308C, with recording continuously at 5–15 min intervals by
including 10 mM ThT in the protein sample. The trends reported
were reproducible by both these methods of incubation and
monitoring. A range of incubation conditions were tested includ-
ing: ‘Tris buffer pH 8.4’ (see above), ‘Tris buffer pH 7.5’ (50 mM
Tris–HCl buffer, pH 7.5, containing 150 mM KCl, 5 mM MgCl2
and 1 mM DTT) and ‘phosphate buffer pH 8.4’ (50 mM phos-
phate buffer, pH 8.4, containing 150 mM KCl, 5% glycerol and
1 mM DTT) at 308C. The stability of Ure2p is higher in Tris
buffer than in phosphate buffer, and higher at pH 8.4 than at
pH 7.5, with the result that the stability of Ure2p is similar in
the latter two buffers [69]. In general, a stronger inhibition
effect by the chaperones was observed in phosphate buffer and
so this buffer was preferred. However, phosphate buffer was
avoided for experiments performed in the presence of nucleo-
tides. The trends reported were reproducible under the
following range of conditions: Tris or phosphate buffer, with or
without 5 per cent glycerol, pH 7.5–8.4. Representative data
are displayed and precise experimental details are given in the
figure legends. As the absolute lag time of Ure2p fibril formation
is sensitive to even small changes in experimental conditions, such
as temperature and shaking speed, experiments were performed
in parallel wherever possible. Data shown in a single figure
panel were always derived from a single parallel experiment
using a single batch of Ure2p or chaperone, and each data point
represents the average of at least three replicate samples. Error
bars indicate the standard error of the mean. Where indicated,
the curves were normalized to the same final fluorescence plateau
value to facilitate comparison and/or data fitting. Unless other-
wise indicated, a fit of the data to a Boltzman sigmoidal curve is
shown. An ATP-regenerating system (50 mg ml21 CK and 8 mM
CP) was included for the experiments involving ATP.(d) Kinetic analysis of fibril growth curves
The fibril formation data (figure 2) were fitted to an analytical
solution of the kinetics of breakable filament assembly [70–74].
Within this framework, the evolution of the fibril mass concen-
tration is given in terms of the rate constants for primary
nucleation (kn), fibril elongation (kþ) and fibril fragmentation
(k2), as well as the concentration (M0) and average length (L0)
of pre-formed seed material if present at zero time. In the case
of a reaction with no pre-formed seeds, the analytical solution
given in references [70–72] predicts that the measured fluor-
escent signal depends upon only two combinations of these
parameters, kn/k2 and kþk2, rather than each of them individu-
ally, reducing the freedom of fits to the model. In figure 2a, the
data are fitted globally to the solution from [70–72] such that
the parameter kn/k2 is fixed globally to a single value across
all of the chaperone concentrations (including for the data in
the absence of chaperone), whereas the second parameter kþk2
is allowed to vary for the data at each individual chaperone con-
centration. An equivalent analysis to that in figure 2a is
performed in figure 2b, with kn/k2 fixed globally across all cha-
perone concentrations to the best global value and kþk2 allowed
to vary for each of the chaperone concentrations. These con-
strained fits, where kn/k2 is fixed to a single value over all
chaperone concentrations, effectively allow only the elongation
rate to vary between different concentrations of chaperone
(assuming k2 and kn are not correlated), revealing that the effect
of Ssalp can be captured primarily by a change in the rate with
which fibrils elongate, with any variations in the rates of the
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Figure 2. Ssa1p inhibits fibril formation of Ure2p in a concentration-
dependent manner. Incubation was in a Perkin-Elmer EnSpire multimode
plate reader at 308C in Tris buffer pH 7.5. Fibril formation was monitored
by in situ measurement of ThT fluorescence. The error bars represent the
standard error of the mean. Data were normalized. Other details are as
described in §2. Ure2p (30 mM) in the absence or presence of different
molar ratios of (a) WT Ssa1p or (b) DA Ssa1p, as indicated. The data are
fitted (solid lines) globally with an analytical model of breakable fibril assem-
bly (see §2); this constrained fit, where only the rate of elongation is affected
by the chaperone, is able to describe the entire dataset. The insets show the
variation in the relative elongation rate with chaperone concentration, as
determined by the fitted rate parameters.
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4other processes being less important in defining the observed
changes in growth profiles. The insets in figure 2a and b show
respectively the variation with Ssa1p and DA Ssa1p concentra-
tion of the relative elongation rates as determined from the
fitted rate parameters.
(e) Electron microscopy
A 10 ml drop of the amyloid fibril formation sample was placed
onto a copper grid coated with a Formvar film. The sample was
then negatively stained with uranyl acetate (2% w/v) and
observed using a Philips Tecnai 20 electron microscope.
( f ) Far-UV circular dichroism spectroscopy
CD spectra were acquired on a Pistar-180 spectrometer (Applied
Photophysics Ltd, UK). Spectra were measured for each protein
sample in Tris buffer pH 8.4 within the range from 195 to
260 nm in a 0.1 cm cuvette at 258C. In each case, three to five
spectra were acquired and then averaged.
(g) Seed preparation
Ure2p (50 mM) was incubated at 48C in Tris buffer pH 8.4 with-
out shaking until fibril formation was complete (approx. 7 days).
The mature fibrils were then sonicated using a probe sonicator
(Sonics and Materials VCX750) for a total of 8 s (in 1 s bursts)
at 23 per cent sonication power to obtain seeds.(h) Quartz crystal microbalance measurements
The attachment of the Ure2p fibril seeds to the gold surface of the
quartz crystal microbalance (QCM) sensor was carried out in a
similar manner to the protocol described previously [75]. A sol-
ution of 5 mM Ure2p sonicated fibril seeds was mixed with a
10-fold molar excess of Traut’s reagent (2-iminothiolane–HCl)
and incubated for 5 min. Then, 100 ml of the mixture was added
onto the gold surface of a QCM sensor for 1.5 h. The surface was
rinsed with ddH2O. Finally, the remaining gold surface was passi-
vated via incubation for 1 hwith a 0.1 per cent solution ofmethoxy
polyethylene glycol thiol (Polypure, Oslo, Norway). The sensor
was rinsed again with water and inserted into the microbalance
flow cell (Q-sense, E4, Q-Sense; Va¨stra Fro¨lunda, Sweden) and
was ready to use after equilibration with Tris buffer pH 8.4 over-
night. For measurements, 300 ml of 1 mM Ure2p solution was
introduced into the tubing and flow cell with a peristaltic pump
at a flow rate of 150 ml min21. The pump was then switched off,
and the measurement was performed in the absence of flow. In
order to evaluate the seed fibril elongation rate under a given set
of conditions, the steady-state part of the induced frequency shift
was fitted to a linear function, and the slope was taken to be
proportional to the elongation rate [76].
(i) Atomic force microscopy
Atomic force microscopy (AFM) was used to assess the mor-
phology of the seeds prepared for attachment to the QCM
sensor and to observe the final state of the QCM-sensor surface
after measurements were complete. The Ure2p fibril seed
sample (10 ml) was dropped onto a freshly cleaved mica surface
and allowed to stand for 5 min. The mica was then washed with
double-distilled water to remove salts and dried with nitrogen
gas. The QCM sensor was also washed with double-distilled
water before use and dried with nitrogen gas. A PicoPlus AFM
(Molecular Imaging, Tempe, AZ, USA) was used for imaging.
( j) Dynamic light scattering
The dynamic light scattering (DLS) signal of 10 mM Ure2p and
10 mM DA Ssa1p, individually or as a mixture, was monitored
using a Malvern Zetasizer Nano ZS instrument (Malvern, UK)
at room temperature in Tris buffer pH 8.4.
(k) Pull-down assay
A 100 ml mixture of 10 mM Ure2p seeds and 20 mM wild-type
(WT) or DA Ssa1p was incubated in Tris buffer pH 8.4 in a
308C water bath for 2 h and then loaded onto the surface of
0.9 ml of a 40 per cent sucrose solution prior to centrifugation
at 61 000 rpm for 30 min in a S140AT rotor at 48C using a Hitachi
CS150GXL centrifuge. The pellets were washed twice and resus-
pended in Tris buffer pH 8.4 containing 1 per cent sodium
dodecyl sulfate (SDS), and boiled for 10 min before applying to
the SDS-polyacrylamide gel electrophoresis (PAGE).3. Results
(a) Ssa1p inhibits Ure2p amyloid fibril formation
ThT fluorescence is widely used to probe the kinetics of Ure2p
amyloid fibril formation, which typically shows a sigmoidal
curve, with an initial lag phase, a subsequent exponential
phase, and finally a plateau phase [69,77,78]. The ThT fluor-
escence assay was used to monitor the fibril formation of
Ure2p in the presence or absence of Ssa1p and its mutants.
Different concentrations of Ssa1p were added to the ThT
assay, such that the molar ratio of Ssa1p/Ure2p ranged
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Figure 3. The inhibition of Ure2p amyloid fibril formation by Ssa1p is nucleotide-independent in the presence and absence of Ydj1p. Experimental conditions were
the same as described in the legend to figure 2. The error bars represent the s.e. of the mean. A sigmoidal fit of the data is shown. (a) Ure2p (30 mM) in the
absence or presence of different molar ratios of Ssa1p, with 1 mM ATP or ADP or without nucleotide, as indicated. (b) Ure2p (30 mM) in the absence or presence of
different molar ratios of Ssa1p and WT or H34Q Ydj1p, with or without 1 mM ATP or ADP, as indicated. Data are shown without normalization. (c) Ure2p (30 mM) in
the absence or presence of an equimolar ratio of WT or H34Q Ydj1p, as indicated.
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5from 0.1 to 1 molar equivalents. Addition of Ssa1p caused the
lag time to be prolonged in a concentration-dependent
manner (figure 2a). The degree of inhibition of Ure2p fibril
formation by Ssa1p was found to be similar in the presence
or absence of ATP or ADP (figure 3a), indicating that inhi-
bition does not require the presence of nucleotide. Even
when lower concentrations of Ssa1p (0.2 molar equivalent
of Ssa1p to Ure2p) were used, no significant effect of the pres-
ence or absence of ATP was observed (figure 3a). The
morphology of fibrils harvested during the plateau phase
was indistinguishable in the presence and absence of chaper-
one, and with or without ATP or ADP, as judged from
electron microscopy (data not shown), suggesting that
Ssa1p simply delays the process of fibril formation without
arresting it completely.
The addition of pre-formed seed fibrils of Ure2p shortens
or circumvents the lag phase; however, when Ssa1p wasadded alongside seed fibrils, the presence of Ssa1p had a
similar inhibitory effect on the fibril formation kinetics as in
unseeded solution (not shown). As further controls, incu-
bation of bovine serum albumin (BSA) with Ure2p had no
effect on Ure2p fibril formation and incubation of Ssa1p
alone showed no ThT fluorescence increase under the same
conditions (not shown).
To investigate at which stages of Ure2p fibril formation
Ssa1p acts, we delayed the addition of Ssa1p to varying
degrees (see the electronic supplementary material, figure
S2). Ssa1p was added at the start of the experiment or at
later time points, corresponding to the beginning, mid-lag
time, early-exponential and late-exponential phases of fibril
formation; for the control sample, an equivalent volume of
buffer was added instead. The lag time was delayed to a simi-
lar extent when Ssa1p was added at the beginning or the
middle of the lag phase (see the electronic supplementary
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Figure 4. Effect of C-terminal deletion of DA Ssa1p on its inhibition of Ure2p
amyloid fibril formation. (a) Fibril formation of 50 mM Ure2p in the absence
or presence of 50 mM WT Ssa1p, DA Ssa1p, DADC20 Ssa1p, DADC30
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error bars represent the standard error of the mean. A sigmoidal fit of the
data is shown. (b) Far-UV circular dichroism spectra of Ssa1p mutants:
4 mM DA Ssa1p, DADC20 Ssa1p, DADC30 Ssa1p, DADC40 Ssa1p and
DADC88 Ssa1p, as indicated.
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6material, figure S2a,b), and a significant delay was still
observed when Ssa1p was added at the beginning of the
exponential phase (see the electronic supplementary material,
figure S2c), suggesting that Ssa1p interacts with species of
Ure2p that are significantly populated during and beyond
the lag phase, such as native protein and/or fibril seeds.
Our results also indicate that Ssa1 does not disaggregate
mature fibrils of Ure2p, even in the presence of ATP, consist-
ent with previous results [57].
As the ATPase activity of Ssa1p is stimulated by the co-
chaperone Ydj1p [39,42] (see the electronic supplementary
material, figure S1a), we also examined the effect of nucleo-
tide on inhibition of Ure2p fibril formation by Ssa1p in the
presence and absence of Ydj1p. The results show that even
in the presence of Ydj1p, the presence or absence of nucleo-
tide has no detectible effect on the ability of Ssa1p to
inhibit the fibril formation of Ure2p (figure 3b). The lag
time of Ure2p fibril formation in the presence of Ssa1p and
Ydj1p (figure 3b) is longer than that in the presence of
Ssa1p alone (figure 3a), which is attributed to the inhibition
effect of Ydj1p, because Ydj1p itself can lengthen the lag
time of Ure2p fibril formation (figure 3c), as reported pre-
viously [57,59]. The J domain of Ydj1p, which can stimulate
the ATPase activity of Ssa1p, is important for curing of
[URE3] in vivo; hence, it has been suggested that the curing
effect of Ydj1p on [URE3] is indirect and occurs via its
effect on Ssa1p [79,80]. We therefore tested the Ydj1p
mutant H34Q, which is deficient in stimulating the ATPase
activity of HSP70 [81,82] and also disables curing of [URE3]
by Ydj1p [79,80]. We found that Ydj1p H34Q shows signifi-
cantly weaker inhibition of Ure2p fibrillation in vitro
compared with WT Ydj1p, both in the presence (figure 3b)
and absence (figure 3c) of Ssa1p, which could account for
the weaker curing effect of Ydj1p H34Q in vivo [79,80].Table 1. Summary of Ssa1p deletion mutants used in this study. NBD,
nucleotide binding domain; SBD, substrate binding domain; CTD, C-terminal
domain; a, a-helix; rc, random coil. See also figure 1.
protein residues domains
WT Ssa1p 1–642 NBD, SBD, CTD
DA Ssa1p 382–642 SBD, CTD
DADC20 Ssa1p 382–622 SBD, CTD (aA-D, part of rc)
DADC30 Ssa1p 382–612 SBD, CTD (aA-D)
DADC40 Ssa1p 382–602 SBD, CTD (aA-C, part of aD)
DADC60 Ssa1p 382–582 SBD, CTD (aA-C)
DADC88 Ssa1p 382–554 SBD, CTD (aA-B)
CTD Ssa1p 523–642 CTD
CTDDC20 Ssa1p 523–622 CTD (aB-D, part of rc)(b) The role of the ATPase and C-terminal lid
domains of Ssa1p in the inhibition of Ure2p
fibril formation
The lack of effect of the presence of nucleotides in the inhi-
bition of Ure2p fibril formation by Ssa1p suggests that this
effect may arise predominantly from the interaction between
Ure2p and the C-terminal region of Ssa1p. In order to investi-
gate the structural basis of the inhibition effect, we designed a
series of deletion or truncation mutants of Ssa1p. Given the
high similarity of the primary structure of HSP70 proteins,
we used the bovine Hsc70 (NBD, SBD and part of CTD) and
DnaK (SBD and CTD) to model the structure of Ssa1p
(figure 1). Based on the predicted structure, we designed the
truncation mutant DA Ssa1p, which consists of residues
382–642 and lacks the ATPase domain (figure 1 and table 1).
When Ure2p fibril formation was carried out in the presence
of DA Ssa1p, the results were similar to those for WT Ssa1p
(figure 2), consistent with the lack of nucleotide dependence
of the effect of WT Ssa1p (figure 3).
Having established that the N-terminal ATPase domain is
not essential for inhibition, we truncated the C-terminal region
of Ssa1p, in order to further define the role of different parts of
the Ssa1p structure on inhibition of fibril formation. Five
double truncation mutants were constructed: D1–381D623–
642 Ssa1p, D1–381D613–642 Ssa1p, D1–381D603–642 Ssa1p,
D1–381D583–642 Ssa1p and D1–381D555–642 Ssa1p, which,in addition to lacking the N-terminal ATPase domain, also
lack 20, 30, 40, 60 or 88 amino acids, respectively, from theC-ter-
minus. For convenience, we therefore refer to these mutants as
DADC20 Ssa1p, DADC30 Ssa1p, DADC40 Ssa1p, DADC60
Ssa1p and DADC88 Ssa1p, respectively (table 1). We then per-
formed Ure2p fibril formation experiments in the presence of
each of these mutants (figure 4a). The effect of DADC20 Ssa1p
was found to be similar to DA Ssa1p, whereas the effect of
further truncation of the C-terminal region reduced the inhi-
bition effect on Ure2p fibril formation in the following
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Figure 5. Effect of the isolated Ssa1p C-terminal a-helical bundle on inhi-
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7pattern: WT Ssa1p  DA Ssa1p  DADC20 Ssa1p. DADC30
Ssa1p DADC40 Ssa1p. DADC60 Ssa1p. DADC88 Ssa1p.
This suggests that truncation of the C-terminal 20 residues of
Ssa1p has few structural or functional consequences with
regard to this assay, whereas truncation of 30, 40, 60 or 88 resi-
dues causes more significant perturbation of structure and/or
removal of residues that contribute to effective inhibition of
fibril formation. This is consistent with the predicted structure
of Ssa1p, in which the C-terminal truncation site for DADC20
Ssa1p is located in the random coil, whereas the truncation
sites for DADC40 Ssa1p, DADC60 Ssa1p and DADC88 Ssa1p
are located within the a-helix bundle, and DADC30 Ssa1p
is truncated close to the border between the random coil
and helix bundle (figure 1). DADC88 Ssa1p, which has the
weakest effect, lacks helices C and D of the a-helix bundle,
whereas DADC60 Ssa1p and DADC40 Ssa1p contain helix C,
but all or part of helix D is truncated (figure 1), indicating
that a-helices C and D each contribute individually to the
ability of the SBD of Ssa1p to inhibit fibril formation of
Ure2p. Interestingly, DADC30 Ssa1p shows a similar degree
of inhibition as DADC40 Ssa1p, although from the predicted
structure, DADC30 Ssa1p is expected to contain an intact helix
D. The far-UV CD spectra of DADC30 and DADC40 Ssa1p
were observed to be similar to each other, but substantially
different to that of DA and DADC20 Ssa1p (figure 4b). This
suggests that the residues in the border region up to and includ-
ing residue 612 (the truncation point for DADC30 Ssa1p)
contribute to the stability and/or structural integrity of helix
D of the a-helix bundle.
In order to test whether the a-helix bundle within the CTD
of Ssa1p is able to bind and inhibit fibril formation of Ure2p
independently of the SBD, we constructed the mutant CTD
Ssa1p; and also the mutant CTDDC20 Ssa1p, which contains
the intact a-helical bundle, but lacks the final 20 residues of
random coil (figure 1 and table 1). As shown in figure 5a,
the CTD mutants of Ssa1p had negligible effect on the fibril
formation of Ure2p, although the CD spectrum of these CTD
mutants confirms they are folded and helical (figure 5b).
While this does not rule out a direct interaction between the
Ssa1p a-helix bundle and Ure2p, it does indicate that the influ-
ence of the C-terminal helical region on binding of the Ure2p
substrate is dependent on the presence of the SBD.
Overall, our results show that the NBD and the C-terminal
random coil regions of Ssa1p do not contribute to inhibition
of Ure2p fibril formation, whereas further truncation of
the C-terminal region reduces the inhibition ability of Ssa1p,
with helices C and D of the a-helix bundle each contributing
to the inhibition effect. On the other hand, the ability of the
a-helix bundle to influence inhibition of Ure2p fibril formation
is dependent on the presence of the SBD. This suggests that
the structural basis of the ability of Ssa1p to inhibit Ure2p
fibril formation resides in the SBD of Ssa1p, but that the
structural integrity of helices C and D in the C-terminal
region also contributes.
(c) An inhibition model based on interaction between
Ssa1p and native Ure2p and/or Ure2p fibril seeds
can fit the kinetic course of Ure2p fibril formation in
the presence of Ssa1p or DA Ssa1p
Chaperone binding to the soluble protein or to fibrillar
species can affect any of the multiple steps in the assemblypathway, which include the formation of new aggregates
from soluble protein (primary nucleation), the elongation of
aggregates and the fragmentation of aggregates. The time
course of fibril formation is largely determined by the rates
of elongation and fragmentation of fibrils, and not by the
rate of primary nucleation events, which enters only as logar-
ithmic corrections in the integrated rate laws [70,83]. Owing
to the predominant dependence of the reaction time course
on the elongation and fragmentation rates, any change in
the amount of available fibrillar ends and/or soluble protein
owing to chaperone binding should be reflected primarily in
a reduced elongation rate. Although interaction of the chaper-
one with the soluble protein may also affect the rate of
primary nucleation, the corresponding effect on the exper-
imental reaction time courses will be much less significant
in comparison with the effect of comparable changes in the
elongation rate.
In order to test this idea, we performed a global fit of the
fibril formation data measured in the presence of varying
concentrations of Ssa1p (figure 2a) with an elongation rate
constant that was allowed to vary for each experiment but
where the primary nucleation rate constant and the
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Figure 6. QCM measurements of Ure2p fibril growth in the presence and absence of DA Ssa1p. The rate of decrease of resonant frequency of the quartz crystal is
proportional to the elongation rate of the surface-bound seed fibrils. (a) This sequence of QCM measurements demonstrates that the elongation rate in the presence
of a mixture of soluble Ure2p and DA Ssa1p is slower (Rf2) than in the absence of the chaperone (Rf1). Renewed incubation with pure Ure2p (Rf3) leads to an
increased rate compared with that during Rf2. However, the rate does not recover fully to the one observed during Rf1, indicating that in addition to the inhibitory
effect of an interaction between the chaperone and the soluble Ure2p, the chaperone is also likely to interact with the seed fibrils on the sensor. (b) Direct com-
parison between the elongation rates of the seeds with 1 mM soluble Ure2p in the presence of 0, 1 or 10 mM DA Ssa1p. (c) AFM image of Ure2p seeds before
commencement of the QCM fibril growth experiment. (d ) AFM image of Ure2p fibrils on the QCM sensor after an experiment, such as the one shown in (a).
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8fragmentation rate constant were held fixed for the entire
dataset. With this constraint, the data were fitted to an
analytical solution [70–72] of the kinetics of breakable fila-
ment assembly (see §2), which describes fibril formation in
terms of three rate constants: nucleation (kn), fibril elongation
(kþ) and fibril fragmentation (k2). This approach accounts
well for the observed trends as can be seen in figure 2a.
The inset in figure 2a shows the variation with Ssa1p concen-
tration of the elongation rate obtained from the fits of the
data. A similar result was obtained by fitting the data
obtained in the presence of DA Ssa1p (figure 2b, inset). This
result indicates that inhibition of Ure2p amyloid fibril for-
mation by Ssa1p or DA Ssa1p is due primarily to an effect
on the rate of fibril elongation.(d) Observation of an interaction between DA Ssa1p
and Ure2p during the course of fibril formation by
biosensor measurements
To obtain independent confirmation of the results from the
ThT kinetic assays, we carried out surface-bound growth
experiments with a quartz crystal microbalance. The principle
of these experiments is to monitor the elongation of surface-
bound amyloid fibrils via changes in the resonant frequency
of the quartz crystal sensor, which are proportional to the
mass increase of the surface-bound fibrils [76]. If the fibrils
are irreversibly attached to the QCM-sensor surface, then the
growth of a constant ensemble can be monitored under vary-
ing conditions [73,75], for example, the presence and absenceof a molecular chaperone. When surface-bound Ure2p amy-
loid fibril seeds are brought into contact with a solution of
Ure2p, the elongation of these seeds leads to a decrease in res-
onant frequency (figure 6a). The rates of change of frequency
are proportional to the elongation rates and can be directly
compared for different conditions (figure 6b). AFM imaging
of the QCM sensor before and after an experiment confirms
that the observed increase in mass corresponded to lengthen-
ing of the fibrils (figure 6c,d).
The reproducibility of this assay of amyloid elongation kin-
etics was confirmed by repeated incubation of the QCM sensor
with a solution of Ure2p under identical conditions (see the
electronic supplementary material, figure S3a). The maximum
variability of the measured growth rates was found to be 30
per cent and so we concluded that changes in rate owing to
a change in solution conditions larger than 30 per cent are sig-
nificant. Before being able to test the influence of a chaperone
on the growth rates of the surface-bound fibrils, we also
needed to minimize the binding of the chaperone to the sur-
face of the quartz crystal, because the induced frequency
shifts stemming from fibril growth and chaperone binding
are difficult to disentangle. To test the extent of chaperone
binding in the absence of Ure2p fibril seeds, we applied WT
Ssa1p or DA Ssa1p onto empty sensors. WT Ssa1p showed
significant binding to the empty sensor, whereas DA Ssa1p
showed minimal non-specific binding (see the electronic
supplementary material, figure S3b). Therefore, only DA
Ssa1p was used in further biosensor experiments.
When the growth rates of the Ure2p amyloid fibrils with
and without stoichiometric amounts of DA Ssa1p were
Table 2. Inhibition effect of DA Ssa1p on Ure2p fibril growth monitored by QCM.
factora DA Ssa1p (1:1 with Ure2p) DA Ssa1p (10:1 with Ure2p) lysozymeb bovine beta lactoglobulinb
Rf1/Rf2 2.3 + 0.2 4.5 + 0.5 1.2 1.1
Rf1/Rf3 1.5 + 0.2 1.4 + 0.3 n.a. 1.02
aThe original rate of the oscillation frequency change when applying only Ure2p solution was defined as Rf1, the rate of oscillation frequency change when
applying the mixture of Ssa1p domain-deletion mutants and Ure2p was defined as Rf2, and the rate of oscillation frequency change when applying Ure2p alone
again is Rf3 (figure 6). The value of Rf1/Rf2, which represents the extent of inhibition due to the presence of chaperone, is displayed. The value of Rf1/Rf3,
which represents the extent to which the fibrils and/or sensor has been modified by previous application of chaperone, is also displayed.
bControl experiments were performed with lysozyme or bovine beta lactoglobulin in place of chaperone. The molecular weights of DA Ssa1p, lysozyme and
bovine beta lactoglobulin are 31, 14 and 18 kDa, respectively.
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9compared, it was found that the presence of the chaperone
decreased the fibril growth rate by a factor of 2.3 (figure 6
and table 2), which is significant according to the reproduci-
bility experiments described earlier. Furthermore, subsequent
incubation of the fibrils with pure Ure2p solution led to a
growth rate lower than that observed before treatment with
the chaperone, with the ratio of rates before and after chaper-
one treatment being 1.5 (table 2). The observation that the
initial rate was not quantitatively recovered can be explained
by an interaction between the chaperone and the seed fibrils
on the QCM sensor, leading to inhibition even in the absence
of soluble chaperone. A similar but stronger inhibitory effect
was observed when the soluble Ure2p protein was mixed
with a 10-fold excess of DA Ssa1p; here, the elongation rate
was reduced by a factor of 4.5 compared with the rate in
the absence of chaperone (figure 6 and table 2). Thus, our
label-free QCM experiments independently confirmed that
DA Ssa1p inhibits the growth of Ure2p fibrils. The mechan-
ism is presumably twofold, involving interaction between
DA Ssa1p with both soluble and fibrillar Ure2p.
To confirm that the observed inhibition was due to a
specific interaction between Ure2p and Ssa1p, we performed
control experiments in which lysozyme and bovine beta lac-
toglobulin replaced the chaperone. No significant inhibition
of fibril elongation could be detected in either case (table 2).
(e) Observation of an interaction between DA Ssa1p
and native Ure2p in solution by dynamic light
scattering
In order to investigate further whether DA Ssa1p interacts
directly with native Ure2p in solution, we used DLS measure-
ments. The diffusion of particles in solution induces
fluctuations in the intensity of scattered light. These fluctu-
ations, which are sensitive to particle size, can be detected by
DLS and provide an indication of the distribution of differ-
ent-sized molecules within a population. When solutions
containing Ure2p, DA Ssa1p or a mixture of both proteins
were analysed by DLS, differences in the hydrodynamic diam-
eters of proteins in the mixture compared with those in pure
preparations were observed. This suggests that Ure2p and DA
Ssa1p interact directly in solution to form a complex (figure 7a).
( f ) Observation of an interaction between Ssa1p and
Ure2p fibril seeds by pull-down assay
In order to investigate further whether Ssa1p and DA Ssa1p
interact directly with Ure2p fibril seeds, we used a pull-downassay. Ure2p fibrils were fragmented by sonication to form
short fibril seeds, which were incubated with WT Ssa1p or
DA Ssa1p. Fibrils were harvested by high-speed centrifugation
and resuspended for SDS–PAGE analysis. In general, oligo-
meric seeds of Ure2p are found in the pellet fraction,
whereas soluble WT Ssa1p or DA Ssa1p appear in the super-
natant fraction (data not shown). However, when the Ure2p
rstb.roya
10seeds were incubated with WT Ssa1p or DA Ssa1p, bands cor-
responding to Ssa1p were observed in the pellet fraction
(figure 7b, lanes 3 and 5). This indicates that WT Ssa1p and
DA Ssa1p interact directly with Ure2p fibril seeds.lsocietypublishing.org
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A number of recent studies indicate that molecular chaperones
exert important influence on amyloid fibril formation and prion
propagation [52,59,79,80,84,85]. Overexpression of the HSP70
homologue Ssa1p is able to cure the [URE3] prion state in
yeast cells [50,86,87] and Ssa1p can inhibit fibril formation in
the presence of ATP in vitro [57,58]. Here, we demonstrate
that Ssa1p inhibits fibril formation of Ure2p in the presence or
absence of ATP or ADP. We show that inhibition is primarily
due to the effect of Ssa1p on the elongation rate of Ure2p
fibril growth, rather than by an effect on nucleation or breakage
of fibrils. We observe interaction between Ssa1p and native
Ure2p as well as Ure2p fibril seeds. Previous results also
suggest interaction between Ssa1p and species that are formed
as intermediates in the course of Ure2p fibril formation [57].
HSP70 is involved in a number of important functions
and is essential for cell viability, so cannot be deleted or sub-
stantially truncated in vivo [23], and the structural basis of
functional roles is even harder to ascertain. In this study,
we used the power of in vitro experiments to dissect out the
structural basis for the role of HSP70 in the regulation of
prion propagation, focusing on the protein determinant of
the [URE3] prion state, Ure2p. It has been reported that
mutations in the NBD of Ssa1p affect [URE3] propagation
in vivo, but not the process of [URE3] elimination [58],
suggesting that these processes have different requirements
for HSP70 activity. This is consistent with our in vitro exper-
iments, which mimic the process of prion elimination.
However, although we do not observe any significant differ-
ence in inhibition of Ure2p fibrillation by Ssa1p with or
without ATP/ADP in vitro, we do not discount the possibility
that this process may indeed be nucleotide-dependent in vivo,
where a range of co-chaperones and cofactors (such as HSP40
and HSP104) cooperate with and regulate HSP70 function.
As chaperones operate as a cooperative network, then the
role and mechanism of individual chaperones is difficult to
dissect in vivo. Because HSP70 cooperates with the co-chaper-
one HSP40, we also checked the combined effect of Ssa1p and
the yeast HSP40 family member, Ydj1p. Ydj1p is reported to
cure [URE3] by overexpression in vivo [88] and to inhibit
Ure2p fibril formation in vitro [57,59]. However, the fact
that mutation of the J domain of Ydj1p impairs its ability to
cure [URE3] led to the suggestion that the curing effect of
Ydj1p occurs indirectly via its stimulation of HSP70 [79,80].
The Ydj1p mutant H34Q is deficient in both stimulation of
the chaperone activity of Ssa1p [81,82] and curing of
[URE3] [79,80]. Our data show that Ydj1p H34Q shows sig-
nificantly weaker inhibition of Ure2p fibrillation compared
with WT Ydj1p in vitro, which accounts for the reduced
extent of curing in the presence of Ssa1p (figure 3) as well
as impaired curing in vivo [79,80]. Therefore, the role of a
direct interaction between Ydj1p and Ure2p in [URE3]
curing clearly cannot be excluded on the basis of the in vivo
data. Ydj1p may interact with Ure2p and play a direct role
in curing of [URE3], in addition to its role in activating the
ATPase activity of Ssa1p.The C-terminal lid of the HSP70 SBD fluctuates between
open and closed conformations. This structural transition is
regulated allosterically by ATP binding and hydrolysis in
the NBD and modulates the affinity of HSP70 for substrate.
The nucleotide-free and ADP states are observed to be rela-
tively heterogeneous, whereas ATP (or ATP-analogue)
bound states show less variability in conformation and the
open state is preferred [30,89–92]. However, open and
closed conformations are populated in all nucleotide states
(ATP, ADP and nucleotide-free), albeit in different pro-
portions [45,92,93]. Further, substrates are involved in
determining the conformation, with protein substrates
favouring a more open conformation than small peptide sub-
strates [45,91]. It has been proposed that the differences in
affinity observed in different nucleotide states are not in
fact due to different conformations per se, but due to the fre-
quency of fluctuation between the open and closed states and
their relative abundance [93]. Much of our understanding of
the HSP70 ATPase cycle and its associated dynamic confor-
mational changes has come from studies using small
peptide substrates, with E. coli DnaK being the most inten-
sively studied HSP70 homologue to date. Important
differences in the regulatory mechanism have been observed
even between closely related HSP70 homologues [91,92],
meaning that extrapolation between different systems must
be done with caution. The lack of structural data for the
yeast homologue Ssa1p is a significant limitation. Further,
there is clear evidence from genetic studies for differences
in the way that ‘normal’ (e.g. heat denatured) and amyloido-
genic or prion substrates are recognized [51]. Nevertheless, in
the light of current understanding of HSP70 structure and
function, the lack of nucleotide (or even NBD) dependence
observed here suggests that the conformational changes
driven by nucleotide binding and hydrolysis are unimportant
on the timescale of the Ure2p fibril formation experiments
and/or that binding to Ure2p locks HSP70 into the preferred
conformation for binding, overriding the conformational
preference of any given nucleotide state.
Having found that the presence or absence of nucleotide
had no significant effect on the ability of Ssa1p to inhibit
Ure2p fibril formation, we tested whether or not entirely
deleting the ATPase domain reduced the inhibition ability
of Ssa1p towards Ure2p and found it did not. We found
that the ATPase domain-deletion mutant (DA Ssa1p) inter-
acted with Ure2p in a similar manner to the full-length
protein. We then went on to examine the effect of progressive
truncation of the Ssa1p C-terminal domain, in order to
further refine the structural regions that are important for
the inhibition effect on Ure2p.
The C-terminal lid is thought to contribute to the oligo-
merization of Ssa1p [94] and provide an acidic environment
for the HSP70 client. When the client protein enters the
groove formed by the b-sheet of the SBD, the C-terminal
lid closes the exit [43,44]. The first a-helix in the a-helix
bundle, a-helix B, swings upwards to form a continuous
helix with a-helix A (the first a-helix in the CTD) resulting
in complete exposure of the substrate binding groove [95].
Recently, Mayer and co-workers [45] proposed that the lid
contacts directly with the substrate and can undergo differ-
ent conformational changes depending on the size of
substrate. In this study, when the C-terminal final 20 resi-
dues comprising part of the random coil part of the lid
domain were deleted, there was no effect on the ability of
rstb.royalsocietypublishing.org
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etions around the border between the C-terminal random
coil region and the a-helical bundle reduced the ability of
Ssa1p to inhibit fibril formation, indicating that this region
may contribute to the structural integrity of the a-helical
bundle. Successive deletion of helices D and C of the a-heli-
cal bundle resulted in incremental weakening of the
inhibition effect of Ssa1p on Ure2p fibril formation. On
the other hand, the a-helical bundle of Ssa1p did not influ-
ence fibril formation of Ure2p in isolation from the SBD.
Taken together, this indicates that the SBD of Ssa1p is pri-
marily responsible for inhibition of Ure2p fibril formation,
and the a-helical bundle of the CTD facilitates this effect.
Interestingly, our results suggest that the a-helical bundle
does not have to be fully formed to contribute to this
effect. These findings are similar to the inhibitory effect of
human HSP70 on aggregation of a-synuclein, which also
relies primarily on the action of the SBD, but is facilitated
by the presence of the CTD [47].
Ssa1p inhibition of fibril formation by Ure2p is efficient
when Ssa1p is added during the lag phase or early exponential
phase of fibril growth, suggesting that Ssa1p interacts with
species present during these phases of growth. Our DLS
data indicate that DA Ssa1p interacts with the native Ure2p
protein in solution which is consistent with previous work
that proposed an interaction between Ssa1p and the native
Ure2p protein [57,60]. We also used a pull-down assay
[47,96,97] to detect the interaction between fibrils and
Ssa1p. WT Ssa1p and DA Ssa1p co-pelleted with Ure2p fila-
ment seeds, which provides an explanation for the delay in
the lag time observed in the ThT experiments. Results from
the pull-down assay also help to explain the incomplete
recovery of the elongation rate after chaperone treatment
observed by QCM, indicating that DA Ssa1p interacts with
Ure2p fibril seeds, forming complexes that could not be com-
pletely dissociated by washing. The small amount ofchaperone that remained bound to seeds on the QCM
sensor reduced the growth rate of Ure2p fibrils. HSP70 has
been proposed to adopt an ‘intermediate-open’ conformation
upon binding to bulky substrates such as protofibrils or
fibrils, where the substrate binding groove is not completely
sealed by the lid [45]. In this case, Ssa1p presumably adopts
an ‘intermediate-open’ conformation to interact with Ure2p
fibril seeds.
Taken together, our results indicate that WT and DA
Ssa1p are able to interact directly with both native Ure2p
and Ure2p fibril seeds, providing an explanation for the
observation of inhibition of fibril formation even in the
absence of nucleotide. We show that this inhibitory effect is
primarily reflected in a reduction in the rate of fibril
elongation. Further, our results concerning the involvement
of the HSP70 CTD in binding are consistent with other
recent results that indicate that the SBD is crucial for substrate
interactions, but binding is enhanced by the presence of the
CTD, either due to direct interaction between the substrate
and the CTD, or due to the action of the CTD as a lid to facili-
tate capture of substrate molecules.
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